TURGEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TURGEX (TURGEX).
TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.
| Metabolism | Primarily metabolized via CYP2D6 and CYP3A4 isoenzymes; also undergoes glucuronidation. Metabolites are largely inactive. |
| Excretion | Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites |
| Half-life | Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment |
| Protein binding | 92% bound, primarily to albumin; slightly reduced (85%) in hypoalbuminemia or chronic liver disease |
| Volume of Distribution | 0.9 ± 0.2 L/kg; indicates extensive tissue distribution with partitioning into well-perfused organs; Vd increases to 1.4 L/kg in obesity |
| Bioavailability | Oral immediate-release: 68% ± 9% (first-pass metabolism by CYP3A4 in gut and liver); Oral extended-release: 55% ± 12% (lower due to incomplete absorption); Subcutaneous: 95% ± 5%; no IV formulation |
| Onset of Action | Intravenous: 2–5 minutes; Oral immediate-release: 30–60 minutes; Oral extended-release: 1–2 hours |
| Duration of Action | Intravenous: 6–8 hours; Oral immediate-release: 8–12 hours; Oral extended-release: 18–24 hours; clinical effect correlates with plasma concentration >0.5 mcg/mL |
| Molecular Weight | 352.45 |
10 mg orally once daily
| Dosage form | EMULSION |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: avoid use |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 5 mg once daily; Child-Pugh C: contraindicated |
| Pediatric use | 0.2 mg/kg orally once daily; maximum 10 mg/day |
| Geriatric use | Start at 5 mg once daily; titrate to response |
| 1st trimester | Contraindicated due to teratogenic effects including neural tube defects and congenital heart anomalies. |
| 2nd trimester | Contraindicated due to risk of fetal hypotension and decreased placental perfusion. |
| 3rd trimester | Contraindicated due to risk of neonatal withdrawal and pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for TURGEX (TURGEX).
| Placental transfer | Extensive placental transfer; fetal plasma levels reach 80-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in significant amounts; may cause infant sedation and poor feeding. Discontinue breastfeeding or avoid drug. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS – Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
Hypersensitivity to TURGEX or any excipientPregnancyBreastfeedingSevere hepatic impairment (Child-Pugh C)Uncontrolled glaucomaConcurrent use with MAO inhibitors
| Precautions | Clinical worsening and suicide risk, Serotonin syndrome: risk increased with co-administration of other serotonergic drugs, Activation of mania/hypomania in bipolar disorder patients, QTc prolongation: risk increased in patients with cardiac disease or electrolyte abnormalities, Seizures: use with caution in patients with seizure disorder, Angle-closure glaucoma: may cause mydriasis, trigger acute attack, Hyponatremia: especially in elderly or volume-depleted patients |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase turgafiban levels by inhibiting CYP3A4. No other significant food interactions. Maintain consistent intake of vitamin K-rich foods if on warfarin concurrently. |
Loading safety data…
| L5 |
| Teratogenic Risk | TURGEX is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid volume by ultrasound every 4 weeks. Assess ductus arteriosus patency after 20 weeks. Maternal monitoring of blood pressure and renal function monthly. |
| Fertility Effects | TURGEX may impair female fertility based on animal studies (prolonged estrous cycle). No human data on male fertility. |
| Clinical Pearls | TURGEX (turgafiban) is a glycoprotein IIb/IIIa inhibitor used in acute coronary syndromes. Monitor platelet count within 6 hours of loading dose and daily during infusion. Discontinue if platelets drop below 100,000/μL. Avoid use with other GP IIb/IIIa inhibitors. Half-life is 2 hours, but platelet function recovery may take 4-6 hours after infusion stop. Co-administer with heparin requires frequent aPTT monitoring. |
| Patient Advice | Report any unusual bruising, bleeding, or blood in urine/stool immediately. · Avoid aspirin, ibuprofen, or other NSAIDs unless prescribed by your doctor. · You will have frequent blood tests to monitor platelet levels. · Do not stop this medication abruptly without consulting your physician. · Use an electric razor and soft toothbrush to minimize bleeding risk. |